Working Paper of Public Health Volume 2012 - Azienda Ospedaliera ...

More documents

Recommendations

Info

Azienda Ospedaliera Nazionale“SS. Antonio e Biagio e Cesare Arrigo”Working Paper of Public Healthnr. 12/2012[12] G. Saia, S. Blandamura,G. Bettini, A. Tronchet, A. Totola,G. Bedogni, G. Ferronato, P.F. Nocini, A. Bedogni, “Occurrence of Bisphosphonate-Related Osteonecrosis of the JawAfter Surgical Tooth Extraction,” Oral Maxillofac Surg., vol. 68 pp.797-804, 2010.[13] M. Biasotto, S. Chiandussi, S. Zacchigna, S. Moimas, F. Dore, G. Pozzato, F. Cavalli, F.Zanconati, L. Contardo, M. Giacca, R. Di Lenarda, “A novel animal model to study nonspontaneousbisphosphonates osteonecrosis of jaw,” J Oral Pathol Med., vol. 39, no. 5, pp.390-396, 2010.[14] M Ardine, D Generali, M Donadio, S Bonardi, M Scoletta, AM Vandone, M Mozzati, OBertetto, A Bottini, L Dogliotti, A Berruti. Could the long-term persistence of low serumcalcium levels and high serum parathyroid hormone levels during bisphosphonate treatmentpredispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol.Aug;17(8): pp 1336-7, 2006.[15] P.G. Arduino, E. Menegatti, M. Scoletta, C. Battaglio, M. Mozzati, A. Chiecchio, D.Berardi, A.M. Vandone, M. Donadio, S. Gandolfo, C. Scully, R. Broccoletti, “Vascularendothelial growth factor genetic polymorphisms and haplotypes in female patients withbisphosphonate-related osteonecrosis of the jaws,” J Oral Pathol Med, vol. 40, no. 6, pp.510-515, 2011.[16] F. Marini, P. Tonelli, L. Cavalli, T. Cavalli, L. Masi, A. Falchetti, M.L. Brandi,“Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw,” Front Biosci(Elite Ed), vol. 1, no. 3, pp. 364-370, 2011.[17] G. Favia, G.P. Pilolli, E. Maiorano, “Histologic and histomorphometric features ofbisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laserscanning microscopy,” Bone, vol. 45, no. 3, pp. 406-413, 2009.[18] A. Alonci, A. Allegra, G. Bellomo, E. Quartarone, G. Oteri, E. Nastro, D. Cicciù, F.S.De Ponte, C. Musolino, “Patients with bisphosphonate-associated osteonecrosis of the jawhave unmodified levels of soluble vascular endothelial growth factor receptor 1,” LeukLymphoma., vol. 48, no. 9, pp. 1852-1854, 2007.[19] G. Oteri, A. Allegra, G. Bellomo, A. Alonci, E. Nastro, G. Penna, L. Catalfamo, D.Cicciù, F.S. De Ponte, C. Musolino, “Reduced serum levels of Interleukin 17 in patients withosteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonatesadministration,” Cytokine., vol. 43, no. 2, pp. 103-104, 2008.[20] A. Allegra, A. Alonci, G. Penna, A. Granata, E. Nastro Siniscalchi, G. Oteri, S. Loddo,D. Teti, D. Cicciù, F.S. De Ponte, C. Musolino, “Bisphosphonates induce apoptosis of10
Azienda Ospedaliera Nazionale“SS. Antonio e Biagio e Cesare Arrigo”Working Paper of Public Healthnr. 12/2012circulating endothelial cells in multiple myeloma patients and in subjects withbisphosphonate-induced osteonecrosis of the jaws,” Acta Haematol., vol. 124, no. 2, pp. 79-85, 2010.[21] E. Nastro Siniscalchi, G. Cutroneo, L. Catalfamo, G. Santoro, A. Allegra, G. Oteri, D.Cicciù, A. Alonci, G. Penna, C. Musolino, F. Saverio De Ponte, G. Anastasi, A. Favaloro,“Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium ofmultiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw,” OncolRep., vol. 24, no. 1, pp. 129-134, 2010.[22] D. Baldi, A. Izzotti, P. Bonica, P. Pera, A. Pulliero, “Degenerative periodontal-diseasesand oral osteonecrosis: the role of gene-environment interactions,” Mutat Res., vol. 667, no.1-2, pp. 118-131, 2009.[23] I. Perrotta, M.G. Cristofaro, M. Amantea, E. Russo, S. De Fazio, V. Zuccalà, F.Conforti, A. Amorosi, G. Donato, S. Tripepi, M. Giudice, “Jaw osteonecrosis in patientstreated with bisphosphonates: an ultrastructural study,” Ultrastruct Pathol., vol. 34, no. 4, pp.207-213, 2010.[24] M.T. Di Martino, M. Arbitrio, P.H. Guzzi, E. Leone, F. Baudi, E. Piro, T. Prantera, I.Cucinotto, T. Calimeri, M. Rossi, P. Veltri, M. Cannataro, P. Tagliaferri, P. Tassone, “Aperoxisome proliferator-activated receptor gamma (PPARG) polymorphism is associatedwith zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysisby DMET microarray profiling,” Br J Haematol, vol. 154, no. 4, pp. 529-533, 2011.[25] G. Ficarra, F. Beninati, I. Rubino, A. Vannucchi, G. Longo, P. Tonelli, G. Pini Prato,“Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonatestreatment,” J Clin Periodontol., vol. 32, no. 11, pp. 1123-1128, 2005.[26] A.M. Vannucchi, G. Ficarra, E. Antonioli, A. Bosi, “Osteonecrosis of the jaw associatedwith zoledronate therapy in a patient with multiple myeloma,” Br J Haematol., vol. 128, no.6, pp. 738, 2005.[27] V. Guarneri, S. Donati, M. Nicolini, S. Giovannelli, R. D'Amico, P.F. Conte, “Renalsafety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for upto 10 Years,” Oncologist., vol. 10, no. 10, pp. 842-848, 2005.[28] A. Oltolina, A. Achilli, G. Lodi, F. Demarosi, A. Sardella, “Osteonecrosis of the jaws inpatients treated with bisphosphonates. Review of the literature and the Milan experience,”Minerva Stomatol., vol. 54, no. 7-8, pp. 441-448, 2005.11
Page 2 and 3:
La serie di Working Paper of Public
Page 4 and 5:
Azienda Ospedaliera Nazionale“SS.
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Azienda Ospedaliera NazionaleSS. An
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79: Azienda Ospedaliera Nazionale“SS.
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
show all

Working Paper of Public Health Volume 2012 - Azienda Ospedaliera ...

Create successful ePaper yourself

Delete template?

Save as template?